Columbia University is at the frontier between AI and biotech, especially in coronavirus research. Two graduates of the Data Science Institute (DSI) at Columbia University – Andrew Satz and Brett Averso – are using AI in coronavirus research, relying on computational design to accelerate the discovery of treatments for the coronavirus. Andrew Satz and Brett Averso are Chief Executive Officer and Chief Technology Officer, respectively, of EVQLV, a startup creating algorithms capable of computationally generating, screening, and optimizing hundreds of millions of therapeutic antibodies. They apply their technology to discover treatments most likely to help those infected by the virus responsible for COVID-19. Conducting antibody discovery in a laboratory typically takes years; it takes just a week for the algorithms to identify antibodies that can fight against the virus.